Double-blind, randomized, controlled, phase 1 study of the safety and immunogenicity of AMA1-C1/alhydrogel vaccine for Plasmodium falciparum malaria, in semi-immune adults in Doneguebougou, Mali

Trial Profile

Double-blind, randomized, controlled, phase 1 study of the safety and immunogenicity of AMA1-C1/alhydrogel vaccine for Plasmodium falciparum malaria, in semi-immune adults in Doneguebougou, Mali

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Malaria vaccine (Primary) ; Aluminium hydroxide
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Feb 2008 The expected completion date for this trial is now 1 Jan 2008.
    • 23 Jan 2008 Status changed from in progress to completed according to NCT.
    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top